Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 42505 10Th Street West LANCASTER CA 93534-7059 |
Tel: | 1-661-7237723 |
Website: | https://www.simulations-plus.com |
IR: | See website |
Key People | ||
Shawn M. O'Connor Chief Executive Officer | William Frederick Chief Financial Officer, Chief Operating Officer, Secretary | John A. Dibella President - PBPK, Regulatory Strategies, Cheminformatics Solutions |
Jill Fiedler-Kelly President - Clinical Pharmacology and Pharmacometric Services | Brett Howell President - Quantitative Systems Pharmacology Solutions | Sandra Suarez Sharp President - Regulatory Strategies | Dan Szot Chief Revenue Officer |
Business Overview |
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics. |
Financial Overview |
For the six months ended 29 February 2024, Simulations Plus Inc revenues increased 18% to $32.8M. Net income increased 10% to $6M. Revenues reflect Software segment increase of 16% to $19.2M, Services segment increase of 22% to $13.6M, Americas segment increase of 22% to $23.4M, Europe segment increase of 21% to $7M. Net income was partially offset by Change in fair valuation of contingent c increase from $0K to $330K (expense). |
Employees: | 192 as of Aug 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $779.03M as of Feb 29, 2024 |
Annual revenue (TTM): | $64.67M as of Feb 29, 2024 |
EBITDA (TTM): | $13.39M as of Feb 29, 2024 |
Net annual income (TTM): | $10.52M as of Feb 29, 2024 |
Free cash flow (TTM): | $7.97M as of Feb 29, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 19,984,945 as of Mar 31, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |